Tennessee Oncology | Association Partnerships

Latest from Tennessee Oncology


Safety of Cilta-Cel in Patients With R/R Multiple Myeloma

March 08, 2022

Jesus Berdeja, MD, discusses the safety profile observed with the newly approved chimeric antigen receptor T-cell therapy, ciltacabtagene autoleucel as observed in the phase 1/2 CARTITUDE-1 clincial trial.

Behind the FDA Approval: Cilta-cel for Treatment of Heavily Pretreated R/R Multiple Myeloma

March 03, 2022

In an interview, Jesus Berdeja, MD, discussed the introduction of ciltacabtagene autoleucel into the treatment landscape for relapsed/refractory multiple myeloma, how it may differ from idecabtagene vicleucel, and the future of CAR T-cell use in the space.